ADVM - NASDAQ
Adverum Biotechnologies, Inc.
$4.36
+0.0000%Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotAdverum Biotechnologies, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Adverum Biotechnologies, Inc. Income Statement
ADVM • NASDAQ
| Adverum Biotechnologies, Inc. Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
1M | 3.6M | 0.0 | 7.5M | 0.0 | 250K | 1.6M | 1.8M | 1.5M | 2.3M | 572K | 480K | 30K | |
GROSS PROFIT | |||||||||||||
(0.0) | (0.0) | (6.5M) | (0.0) | (4.2M) | (0.0) | (0.0) | (2.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
1M | 3.6M | -6.5M | 7.5M | -4.2M | 250K | 1.6M | -247K | 1.5M | 2.3M | 572K | 480K | 30K | |
OPERATING INCOME | |||||||||||||
(140.2M) | (132.5M) | (148.5M) | (153.6M) | (113.8M) | (68.8M) | (74.7M) | (60.7M) | (56M) | (47.6M) | (25M) | (3.5M) | (1.8M) | |
(63.1M) | (55.1M) | (57.9M) | (64.4M) | (44.6M) | (28.4M) | (24.6M) | (20.9M) | (24.4M) | (22.1M) | (8M) | (1.8M) | (536K) | |
(77M) | (77.5M) | (99.3M) | (89.2M) | (73.3M) | (40.4M) | (50.1M) | (39.8M) | (31.7M) | (25.5M) | (17M) | (2.2M) | (1.3M) | |
-139.2M | -128.9M | -155M | -146.1M | -118M | -68.5M | -78.1M | -58.8M | -115.3M | -47.8M | -24.4M | -3.5M | -1.8M | |
PRE-TAX INCOME | |||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (18K) | (73K) | (8K) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -18K | 0.0 | 0.0 | |
(0.0) | (0.0) | -8.7M | (0.0) | -4.2M | (0.0) | (0.0) | (2.7M) | (0.0) | (370K) | (0.0) | -96K | -6K | |
8.2M | 5.7M | 549K | 582K | 1.6M | 4.1M | -796K | 2.7M | -62.1M | -2.1M | -1M | -1.8M | 5K | |
-130.9M | -123.2M | -154.5M | -145.5M | -116.4M | -64.5M | -73.9M | -56.1M | -114.5M | -47.5M | -25.4M | -5.3M | -1.8M | |
NET INCOME | |||||||||||||
(0.0) | -1.1M | (74K) | (0.0) | (1.1M) | (0.0) | -1.3M | (0.0) | -775K | (1.8M) | -162K | -23K | (2K) | |
-130.9M | -122.1M | -154.5M | -145.5M | -117.5M | -64.5M | -72.6M | -56.1M | -113.7M | -47.5M | -25.4M | -5.3M | -1.8M |
SEC Filings
ADVM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | December 09, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 04, 2025 | December 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 19, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 24, 2025 | October 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 22, 2025 | September 22, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 12, 2025 | August 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 18, 2025 | June 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 14, 2025 | March 31, 2025 | 2025 |
Related Guides
Continue your ADVM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.